Healthcare
XTL Biopharmaceuticals Ltd.(XTLB)
Live Price
Offline$2.54
+4.96% today
1Y Change
-37.75%
Window
Jun 23, 2025 → Jun 18, 2026
- Market Cap
- $10.00M
- Revenue Growth
- 0.0%
- EPS Growth
- 0.0%
- Dividend Yield
- 0.0%
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
XTL Biopharmaceuticals Ltd. (XTLB) is a Healthcare stock with a market cap of $10.00M and listed on NASDAQ. The stock last traded around $2.54 and down 37.7% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of 0.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS 0.0%, free cash flow -136.5% with operating margin -481.6% and ROIC -29.7%. Valuation already assumes a fairly strong business story at price/sales 19.2. Stock Foundry combines XTLB price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
-481.6% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is 0.0%, while operating margin sits near -481.6%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
XTLB
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
XTLB Max Drawdown
-74.88%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for XTLB and SPY.
Company Overview
XTL Biopharmaceuticals Ltd.
NASDAQ Capital Market
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
- Leadership
- Noam Band
- IPO Date
- Sep 1, 2005
- Employees
- 10
- Street Address
- 5 Badner Street
- Mailing
- Ramat Gan, 5218102
- Region
- Ramat Gan, IL
- Reporting Currency
- USD
- Investor Line
- 972 3 611 6600
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- —
- EV/EBITDA
- —
- Price/Sales
- 19.2
- Price/Book
- 1.1
Growth
- Revenue
- 0.0%
- EPS
- 0.0%
- Free Cash Flow
- -136.5%
Profitability
- Gross Margin
- 0.7%
- Operating Margin
- -481.6%
- Net Margin
- -227.7%
- ROE
- -26.8%
- ROIC
- -29.7%
Balance Sheet
- Debt/Equity
- 0.03
- Current Ratio
- 0.61
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.